

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED

武夷國際藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that it is presently expected that the consolidated net profits of the Group for the six months period ended 30 June 2010 is likely to record a decline as compared to the consolidated net profit for the six months period ended 30 June 2009.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wuyi International Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that having assessed the currently available information, the Group is likely to record a decline in the consolidated net profit for the six months period ended 30 June 2010 as compared with the consolidated net profit for the six months period ended 30 June 2009. The Board considers that the Group’s financial performance has been affected mainly by the following reasons:

1. The turnover of the Group has remained unsatisfactory as a result of some manufacturers continued producing imitated products, which affected and eroded our market shares after the expiry of the protection period of our pharmaceutical products;
2. As the State Food and Drug Administration of the People’s Republic of China has from time to time imposed new restriction and quality requirements on various aspects of Chinese medicine injection, the society’s attitude towards accepting Chinese medicine injection have been changed, which lead to a decline in the

- demand for Chinese medicine injection, therefore the Group's sales of traditional Chinese medicine products was affected; and
3. The drop in gross profit margin of the Group as a result of the increased depreciation charges in cost of sales..

As the Company is still in the process of finalizing its interim results for the six months period ended 30 June 2010, the information contained in this announcement is a preliminary estimate by the management of the Group according to the management account of the Group and is not based on any figures or information that has been audited or reviewed by the Company's auditor. Further details of the Group's performance will be disclosed when the Group's interim results for the six months ended 30 June 2010 are announced.

Despite the lower profit for the six months period ended 30 June 2010, the Board considers that the Group's overall financial position is still healthy and the Board remains positive on the long term prospect of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wuyi International Pharmaceutical Company Limited
Lin Ou Wen
Chairman and Chief Executive Officer

Hong Kong, 23 July 2010

As at the date of this announcement, the Board comprises 3 Executive Directors, namely Mr. Lin Ou Wen (Chairman), Mr. Lin Qing Ping and Mr. Xu Chao Hui, 2 Non-executive Directors, namely Mr. Tang Bin and Mr. John Yang Wang, and 3 Independent Non-executive Directors, namely, Mr. Liu Jun, Mr. Lam Yat Cheong and Mr. Du Jian.